Last reviewed · How we verify

recombinant FSH

University of Colorado, Denver · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

recombinant FSH is a Small molecule drug developed by University of Colorado, Denver. It is currently FDA-approved. Also known as: rFHS, Gonal-f, Puregon, Gonal-F.

Recombinant FSH is used to treat conditions such as female infertility, infertility, controlled ovarian hyperstimulation, multifollicular stimulation, and non-obstructive azoospermia. It belongs to the class of hydrolytic enzymes and works by hydrolyzing hyaluronic acid, according to its mechanism of action.

At a glance

Generic namerecombinant FSH
Also known asrFHS, Gonal-f, Puregon, Gonal-F, Follitrophin-beta
SponsorUniversity of Colorado, Denver
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about recombinant FSH

What is recombinant FSH?

recombinant FSH is a Small molecule drug developed by University of Colorado, Denver.

Who makes recombinant FSH?

recombinant FSH is developed and marketed by University of Colorado, Denver (see full University of Colorado, Denver pipeline at /company/university-of-colorado-denver).

Is recombinant FSH also known as anything else?

recombinant FSH is also known as rFHS, Gonal-f, Puregon, Gonal-F, Follitrophin-beta.

What development phase is recombinant FSH in?

recombinant FSH is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing